Literature DB >> 2195340

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

B Levine1, J Kalman, L Mayer, H M Fillit, M Packer.   

Abstract

BACKGROUND AND METHODS: Although cachexia often accompanies advanced heart failure, little is known about the causes of the cachectic state. To assess the potential role of tumor necrosis factor in the pathogenesis of cardiac cachexia, we measured serum levels of the factor in 33 patients with chronic heart failure, 33 age-matched healthy controls, and 9 patients with chronic renal failure.
RESULTS: Mean (+/- SEM) serum levels of tumor necrosis factor were higher in the patients with heart failure (115 +/- 25 U per milliliter) than in the healthy controls (9 +/- 3 U per milliliter; P less than 0.001). Nineteen of the patients with chronic heart failure had serum levels of tumor necrosis factor greater than or equal to 39 U per milliliter (greater than 2 SD above the mean value for the control group), whereas the remaining 14 patients had serum levels of tumor necrosis factor below this level. The patients with high levels of tumor necrosis factor were more cachectic than those with low levels (82 +/- 3 vs. 95 +/- 6 percent of ideal body weight, respectively; P less than 0.05) and had more advanced heart failure, as evidenced by their higher values for plasma renin activity (2.92 +/- 0.53 vs. 1.06 +/- 0.53 ng per liter per second [10.5 +/- 1.9 vs. 3.8 +/- 1.9 ng per milliliter per hour]; P less than 0.01) and lower serum sodium concentration (135 +/- 1 vs. 138 +/- 1 mmol per liter; P less than 0.05). The group with high levels of tumor necrosis factor also had lower hemoglobin levels (7.82 +/- 0.2 vs. 8.69 +/- 0.4 mmol per liter [12.6 +/- 0.4 vs. 14.0 +/- 0.6 g per deciliter]) and higher values for blood urea nitrogen (19.5 +/- 2.2 vs. 12.5 +/- 1.8 mmol per liter) than the group with low levels of tumor necrosis factor (P less than 0.05 for both). The high levels of tumor necrosis factor were not due solely to decreased renal clearance, however, since the levels in the patients with heart failure were considerably higher than those in the nine patients with chronic renal failure (115 +/- 25 vs. 45 +/- 25 U per milliliter; P less than 0.05).
CONCLUSIONS: These findings indicate that circulating levels of tumor necrosis factor are increased in cachectic patients with chronic heart failure and that this elevation is associated with the marked activation of the renin-angiotensin system seen in patients with end-stage cardiac disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2195340     DOI: 10.1056/NEJM199007263230405

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  494 in total

Review 1.  Clinical implications of tumour necrosis factor alpha antagonism in patients with congestive heart failure.

Authors:  G Torre-Amione; S S Stetson; J A Farmer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  The pharmacokinetics of etanercept in patients with heart failure.

Authors:  O Soran; A M Feldman; V M Schneider; R Hanna; D L Mann; J M Korth-Bradley
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 3.  Cytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance.

Authors:  K Yamauchi-Takihara; T Kishimoto
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

Review 4.  Activation of cytokines as a mechanism of disease progression in heart failure.

Authors:  B Bozkurt
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 5.  Role of nitric oxide in the regulation of substrate metabolism in heart failure.

Authors:  Fabio A Recchia
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

Review 6.  Molecular and cellular mechanisms of myocardial remodeling.

Authors:  Melanie Maytin; Wilson S Colucci
Journal:  J Nucl Cardiol       Date:  2002 May-Jun       Impact factor: 5.952

7.  Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance.

Authors:  Denice M Hodgson; Leonid V Zingman; Garvan C Kane; Carmen Perez-Terzic; Martin Bienengraeber; Cevher Ozcan; Richard J Gumina; Darko Pucar; Fergus O'Coclain; Douglas L Mann; Alexey E Alekseev; Andre Terzic
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

8.  Are cardiovascular diseases a subspeciality of clinical immunology?

Authors:  Pier Luigi Meroni; Piersandro Riboldi
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

9.  Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril.

Authors:  Takashi Yokota; Tomohiro Osanai; Kenji Hanada; Motoi Kushibiki; Naoki Abe; Koichi Oikawa; Hirofumi Tomita; Takumi Higuma; Jin Yokoyama; Hiroyuki Hanada; Ken Okumura
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

10.  Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study.

Authors:  Catherine N Marti; Hassan Khan; Douglas L Mann; Vasiliki V Georgiopoulou; Kirsten Bibbins-Domingo; Tamara Harris; Annemarie Koster; Anne Newman; Stephen B Kritchevsky; Andreas P Kalogeropoulos; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-12-09       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.